March 3, 2026Open Access

Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2– metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study

Key Points

Molecular dynamics reveal treatment-specific differences between CDK4/6 inhibitors in breast cancer therapy.
The study utilized ctDNA-based methylation and fragmentomic profiling to assess biological responses.
Observational analysis using liquid biopsy-based biomarkers showed potential for clinical relevance.
Preliminary findings highlight the need for further validation in larger cohorts with more detail on treatment timing.

Abstract

ctDNA-based methylation and fragmentomic profiling revealed exploratory, treatment specific molecular dynamics, highlighting biological differences between CDK4/6 inhibitors. These findings support the feasibility of liquid biopsy-based biomarker studies in this setting, although their potential clinical relevance remains preliminary and requires validation in larger cohorts with earlier and more granular on-treatment timepoints.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Noto et al. (Wed,) studied this question.

synapsesocial.com/papers/69a75b7fc6e9836116a22ea9 https://doi.org/https://doi.org/10.1016/j.breast.2026.104703

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper